April 22 (Reuters) - Enzo Biochem Inc ::ENZO BIOCHEM - UNIT ENTERED INTO SETTLEMENT, LICENSE AGREEMENT WITH HOLOGIC, GRIFOLS S.A TO SETTLE ALL OUTSTANDING PATENT DISPUTES AMONG THE PARTIES.ENZO BIOCHEM - TERMS OF AGREEMENT INCLUDE ONE-TIME PAYMENTS OF $14 MILLION TO CO IN EXCHANGE FOR FULLY PAID-UP, WORLDWIDE LICENSES TO HOLOGIC & GRIFOLS.
Full Article
March 29 (Reuters) - Grifols SA ::PRESENTS NEW DATA TO SUPPORT THE EFFECTIVENESS OF ITS CLINICAL TRIAL TO TREAT ALZHEIMER'S nL8N1X911P.SAYS LATEST RESULTS SHOW BOTH MILD AND MODERATE PATIENTS IMPROVE AFTER TREATMENT WITH AMBAR PROTOCOL.RESULTS COMPLEMENT AND CONFIRM THOSE PRESENTED IN OCTOBER, NOT ONLY FOR PATIENTS WITH MODERATE-PHASE ALZHEIMER BUT ALSO IN MILD PHASE OF DISEASE.POSITIVE EFFECT OF TREATMENT IS OBSERVED IN ALL COGNITIVE ASPECTS ANALYZED SO FAR IN TRIAL, FOR ALL PATIENTS, BOTH MILD AND MODERATE.IN PATIENTS WITH MODERATE PHASES OF THE DISEASE WHO WERE ANALYZED SEPARATELY, THE AREA THAT PRESENTS MORE POSITIVE RESULTS IS MEMORY.GRIFOLS WILL CONTINUE ITS LINE OF RESEARCH IN THIS FIELD, IN DECEMBER ALL ANALYZES MENTIONED IN THE STUDY WILL BE AVAILABLE.
Full Article
March 7 (Reuters) - Grifols ::SAYS GRIFOLS AND SHANGHAI RAAS BLOOD PRODUCTS CO. LTD. HAVE SIGNED AGREEMENT FOR ASSET PURCHASE BY SHARE ISSUE.SAYS TO BUY 26.2 PERCENT OF VOTING AND ECONOMIC RIGHTS IN SR.WILL CONTRIBUTE 45 PERCENT ECONOMIC RIGHTS IN ITS US SUBSIDIARY GRIFOLS DIAGNOSTICS SOLUTIONS (GDS).AFTER TRANSACTION MAIN SHAREHOLDERS IN SR WILL BE CREAT GROUP (26.7%), GRIFOLS (26.2%) AND RAAS CHINA LTD (25.8%).SAYS TO HAVE RIGHT TO APPOINT THREE DIRECTORS IN SR AND SR TO APPOINT ONE DIRECTOR IN GDS.WILL CONTINUE TO HOLD 55 PERCENT ECONOMIC RIGHTS AND 60 PERCENT VOTING RIGHTS IN GDS.SAYS SR TO BE EXCLUSIVE DISTRIBUTOR OF GRIFOLS BIOSCIENCE AND DIAGNOSTIC PRODUCTS IN CHINA.WILL HOLD VETO RIGHT ON CERTAIN DECISIONS SUCH AS ISSUE OF SHARES, DISPOSAL OF ASSETS, MERGERS AND OTHER.CREAT AGREED NOT TO SELL ITS STAKE IN SR TO COMPETITOR OF GRIFOLS AND GRIFOLS WILL NOT BE ABLE TO SELL ITS STAKE IN GDS TO TO ANY CHINESE CO.SAYS DOES NOT NEED ANY SOURCE OF EXTERNAL FUNDING TO CARRY OUT THE TRANSACTION.GDS VALUATION IS $4.28 BILLION AND RMB 7.50 THE PRICE PER SHARE OF SHANGHAI RAAS.TRANSACTION IS EXPECTED TO BE CLOSED IN SECOND HALF OF 2019.
Full Article
Feb 28 (Reuters) - Grifols SA ::FY NET PROFIT 596.6 MILLION EUROS VERSUS 662.7 MILLION EUROS YEAR AGO.FY NET SALES 4.49 BILLION EUROS VERSUS 4.32 BILLION EUROS YEAR AGO.FY EBITDA REPORTED 1.22 BILLION EUROS VERSUS 1.22 BILLION EUROS YEAR AGO.FY RESEARCH AND DEVELOPMENT NET INVESTMENT 291.4 MILLION EUROS VERSUS 266.3 MILLION EUROS YEAR AGO.
Full Article
Feb 7 (Reuters) - Grifols SA ::GRIFOLS RECEIVES FDA APPROVAL FOR PROCLEIX BABESIA ASSAY FOR DONOR SCREENING ON PROCLEIX PANTHER SYSTEM.
Full Article
Nov 21 (Reuters) - Grifols ::SAYS STARTED TALKS WITH SHANGHAI RAAS BLOOD PRODUCTS TO MAKE INVESTMENT IN THIS COMPANY LISTED IN SHENZHEN STOCK EXCHANGE.TO INVEST IN CO THROUGH GRIFOLS DIAGNOSTIC SOLUTIONS INC AND ITS SUBSIDIARIES, RECEIVING IN EXCHANGE SHANGHAI RAAS NEWLY ISSUED SHARES.SAYS VALUATION OF 100 PERCENT SHARES OF GRIFOLS DIAGNOSTIC SOLUTIONS IS ABOUT $5 BILLION.
Full Article
Nov 2 (Reuters) - Grifols SA ::SAYS APPROVES INTERIM DIVIDEND OF 0.20 EURO PER SHARE TO BE PAID ON DEC. 4.
Full Article
Oct 29 (Reuters) - Grifols SA ::SAID ON SATURDAY THAT AMBAR CLINICAL TRIAL DEMONSTRATED THE ABILITY TO SLOW DOWN THE PROGRESSION OF THE DISEASE IN MODERATE ALZHEIMER'S DISEASE (AD) PATIENTS.THE RESULTS IN THE PRESPECIFIED COHORT OF THE PATIENTS SHOWED A REDUCTION OF 61% IN DISEASE PROGRESSION IN BOTH PRIMARY EFFICACY ENDPOINTS MEASURING COGNITION AND ACTIVITIES OF DAILY LIVING DURING A 14 MONTH PERIOD .AMBAR (ALZHEIMER MANAGEMENT BY ALBUMIN REPLACEMENT) AIMS TO EVALUATE WHETHER AD CAN BE STABILIZED BY PERIODICALLY EXTRACTING PLASMA AND REPLACING IT WITH ALBUMIN .
Full Article
Oct 22 (Reuters) - Grifols SA ::SAYS VIA UNIT SUBSCRIBES FOR MECWINS' SHARES FOR 2 MILLION EUROS REACHING 25 PERCENT IN THE CO.MECWINS FOCUSES ON DEVELOPMENT OF ULTRASENSITIVE IMMUNOASSAYS FOR DETECTION OF PROTEIN BIOMARKERS.
Full Article
Oct 3 (Reuters) - Grifols SA ::SAYS DISAGREES WITH UBS REPORT CONCLUSIONS IN RELATION TO POTENTIAL IMPACT OF FCRN INHIBITORS ON CO'S IMMUNOGLOBULIN BUSINESS.SAYS REPORT IS BASED SOLELY ON PRELIMINARY CLINICAL STUDIES WITH LIMITED NUMBER OF PATIENTS, THUS RESULTS ARE NOT CONCLUSIVE.
Full Article
Earnings vs. 
Estimates